Livforsakringsbolaget Skandia Omsesidigt Has $1.35 Million Holdings in Natera, Inc. $NTRA

Key Points

• Livforsakringsbolaget Skandia Omsesidigt significantly increased its stake in Natera, Inc. by 788.3%, acquiring an additional 7,095 shares in the 2nd quarter, bringing its total holdings to 7,995 shares valued at $1,351,000.
• Natera's stock is currently trading at $175.01, with a market cap of $24.02 billion, while it reported a revenue increase of 32.2% year-over-year to $546.60 million, despite missing EPS estimates.
• Insider trading activity includes the sale of shares by both Solomon Moshkevich and Rowan E. Chapman, resulting in a total of 56,423 shares sold in the last quarter, valued at approximately $8.46 million.

Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 788.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,995 shares of the medical research company's stock after buying an additional 7,095 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt's holdings in Natera were worth $1,351,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Natera in the 1st quarter valued at $1,136,000. Swedbank AB increased its holdings in shares of Natera by 48.8% in the first quarter. Swedbank AB now owns 45,135 shares of the medical research company's stock worth $6,383,000 after purchasing an additional 14,809 shares during the period. Strs Ohio bought a new position in shares of Natera during the first quarter valued at about $8,992,000. Geneos Wealth Management Inc. lifted its holdings in Natera by 142.9% in the first quarter. Geneos Wealth Management Inc. now owns 1,098 shares of the medical research company's stock worth $155,000 after buying an additional 646 shares during the period. Finally, IFM Investors Pty Ltd purchased a new position in Natera in the 1st quarter worth approximately $3,498,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total value of $499,860.00. Following the sale, the insider owned 120,859 shares of the company's stock, valued at approximately $20,137,526.58. The trade was a 2.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 5,079 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $166.53, for a total value of $845,805.87. Following the sale, the chief executive officer owned 158,514 shares of the company's stock, valued at approximately $26,397,336.42. This trade represents a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,423 shares of company stock valued at $8,459,656 in the last three months. 5.63% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on NTRA shares. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Morgan Stanley reissued an "overweight" rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Stephens reiterated an "overweight" rating and set a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Finally, Barclays reissued an "overweight" rating and issued a $210.00 target price (up from $190.00) on shares of Natera in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of "Buy" and an average price target of $194.00.

Natera Stock Up 0.7%

NASDAQ:NTRA traded up $1.25 during midday trading on Friday, hitting $181.11. The stock had a trading volume of 1,489,046 shares, compared to its average volume of 858,746. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The company has a market capitalization of $24.86 billion, a price-to-earnings ratio of -94.82 and a beta of 1.68. The stock has a 50-day moving average of $156.80 and a 200 day moving average of $155.09.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.